- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Phase 3 Study Results Supporting U.S. FDA and European Commission Approvals of STELARA® in the Treatment of Moderately to Severely Active Crohn’s Disease Published in The New England Journal of Medicine
Data from Three Pivotal Phase 3 Studies Detail Efficacy and Safety of First and Only Anti-interleukin-12 and 23 Monoclonal Antibody in Inducing and Maintaining Clinical Response and Remission after One Year of Treatment
New Phase 3 Monotherapy Study of Sirukumab Versus Humira® And Sirukumab Data In An Anti-Tnf Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
Anti-Interleukin-6 Monoclonal Antibody Sirukumab Efficacy and Safety Findings from SIRROUND-H and SIRROUND-T Trials Presented for the First Time at the 2016 ACR/ARHP Annual Meeting
Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking Remicade® (Infliximab) Compared To Ct-P13 (Infliximab Biosimilar)
Studies Presented at the 2016 ACR/ARHP Annual Meeting Reveal Higher Discontinuation Rates in Patients Newly Beginning or Switching to Treatment with CT-P13
Janssen Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial
Following Positive Phase 3 Results in Moderate to Severe Plaque Psoriasis, Guselkumab Represents the First Specific Anti-Interleukin-23 Monoclonal Antibody to Demonstrate Significant Improvement in Signs and Symptoms of Active Psoriatic Arthritis
New Phase 3 Data Show Simponi Aria® (Golimumab) Significantly Improved Signs And Symptoms In Patients With Active Ankylosing Spondylitis
Patients with Painful Inflammatory Spinal Arthritis Showed Marked Improvements in Multiple Study Endpoints Following Treatment with SIMPONI ARIA®
European Commission Approves Stelara® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease
First Interleukin (IL)-12/23 Inhibitor Licensed For Crohn’s Disease